You are here: Industry Insights > Kevzara

News List

Scientists find five key genes are linked to severe COVID-19 expresspharma
December 14, 2020
The genes - called IFNAR2, TYK2, OAS1, DPP9 and CCR2 – partially explain why some people become desperately sick with COVID-19.
Further clinical trials testing Kevzara as COVID-19 therapy to be halted europeanpharmaceuticalreview
September 03, 2020
After Kevzara (sarilumab) did not meet its primary or secondary endpoints in a Phase III trial, Sanofi and Regeneron have said they do not expect to conduct further studies on the drug against COVID-19.
Sanofi provides update on Kevzara® (sarilumab) Phase 3 trial in severe and critically ill COVID-19 patients outside the U.S. worldpharmanews
September 02, 2020
Sanofi announced that the global Phase 3 trial investigating intravenously administered Kevzara® (sarilumab) at a dose of 200 mg or 400 mg[1] in severely or critically ill[2] patients hospitalized with COVID-19 did not meet its primary endpoint and ...
Kevzara fails in PhIII COVID-19 trial pharmatimes
September 02, 2020
Sanofi and Regeneron's rheumatoid arthritis drug Kevzara (sarilumab) has failed to hit targets in a late-stage trial involving patients hospitalised with COVID-19, signalling the end of its development in this area.
Sanofi and Regeneron provide update on Kevzara® (sarilumab) Phase 3 U.S. trial in COVID-19 patients worldpharmanews
July 14, 2020
Sanofi and Regeneron Pharmaceuticals, Inc. announced that the U.S. Phase 3 trial of Kevzara® (sarilumab) 400 mg in COVID-19 patients requiring mechanical ventilation did not meet its primary and key secondary endpoints when Kevzara was added to ...
Regeneron, Sanofi arthritis drug fails COVID-19 study expresspharma
July 06, 2020
Previous trial results had shown that the drug did not help patients with less severe COVID-19, the disease caused by the novel coronavirus.
Sanofi, Regeneron's pull plug on Kevzara COVID-19 trial pharmatimes
July 03, 2020
Sanofi and Regeneron have reported that a late-stage trial assessing the potential of arthritis drug Kevzara (sarilumab) has been stopped after it failed to hit targets.
Regeneron, Sanofi Release Preliminary Phase II Kevzara Results in COVID-19 contractpharma
April 28, 2020
Kevzara rapidly lowered C-reactive protein (CRP), a key marker of inflammation, meeting the primary endpoint.
First patient outside U.S. treated in global Kevzara® (sarilumab) clinical trial program for patients with severe COVID-19 worldpharmanews
April 03, 2020
The first patient outside of the U.S. has been treated as part of a global clinical program evaluating Kevzara® (sarilumab) in patients hospitalized with severe COVID-19.
Global trial to evaluate Kevzara® (sarilumab) as COVID-19 therapy initiated europeanpharmaceuticalreview
March 31, 2020
A Phase II/III trial to study Kevzara (sarilumab) as a method to reduce the inflammatory response in the lungs of COVID-19 patients has begun outside of the US.

Previous page 1 2 Next page